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Stiff person syndrome in South Asia
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Abstract 
Background: Stiff person syndrome is a highly disabling, progressive autoimmune disorder of the central nerv-
ous system characterized by muscle rigidity and spasms. Stiff person syndrome is rare, but is believed to be under 
diagnosed with only 14 cases been reported among a 1.7 billion population in South Asia. We report the first authen-
ticated case from Sri Lanka.
Case presentation: A 55-year-old Sri Lankan female presented with difficulty in walking and recurrent falls due 
to progressive muscular rigidity in her lower limbs and trunk with superimposed muscle spasms that occurred in 
response to unexpected noise, startle or emotional upset. She had anxiety and specific phobias to open spaces, walk-
ing unaided and being among crowds of people. She had insulin-dependent diabetes mellitus and was on thyroxine 
replacement. On examination, she had hyperlordosis combined with board-like rigidity of her anterior abdomen and 
rigidity of her lower limbs bilaterally. Upper limbs were normal. Magnetic resonance imaging of her neuraxis was nor-
mal. Electromyography showed continuous motor unit activity at rest. Glutamic acid decarboxylase antibodies were 
detected in her serum at a titre of 15,500 IU/ml (normal <5). She showed a remarkable and sustained improvement 
to treatment with intravenous immunoglobulins, immunosuppressive and muscle relaxant medications, regaining 
independent ambulation.
Conclusions: Diagnosis of stiff person syndrome remains clinical, supported by electromyography and serology for 
glutamic acid decarboxylase antibodies, facilitated by a high index of clinical suspicion. An autoimmune basis lends 
stiff person syndrome amenable to treatment highlighting the importance of diagnosis. This case adds to map the 
worldwide distribution of stiff person syndrome.
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Background
Stiff person syndrome (SPS), first described by Moersch 
and Woltman in 1956, is a rare, highly disabling, progres-
sive autoimmune disorder of the central nervous system 
(CNS) characterized by muscle rigidity and spasms [1]. 
Since its original description, several variants of the syn-
drome including stiff limb syndrome, jerking SPS, para-
neoplastic SPS and progressive encephalomyelitis with 
rigidity and myoclonus have been described [2]. High 
titres of autoantibodies to glutamic acid decarboxylase 
(GAD), the rate-limiting enzyme in the synthesis of the 
inhibitory neurotransmitter gamma-amino butyric acid 
(GABA), have been reported in approximately 60–80  % 
of patients with classic SPS [3]. However, SPS remains a 
clinical diagnosis facilitated by a high index of suspicion. 
SPS has an estimated prevalence of 1/million population 
[4], but is believed to be underdiagnosed [5]. Thus far, 
only 14 cases have been reported from South Asia, which 
has a collective population of over 1.7 billion. We report 
the first authenticated case of classic SPS from Sri Lanka.
Case presentation
A 55-year-old Sri Lankan female presented with pro-
gressive difficulty in walking superimposed with muscle 
spasms since 2002. She had first noted intermittent stiff-
ness in her right lower limb which lasted about 5–10 min 
at a time but gradually, over months, increased in fre-
quency and duration to be persistent. She then noted 
the stiffness spreading to involve her left lower limb 
making ambulation increasingly difficult. From about 
2009, the muscles of her trunk and lower limbs would 
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go into severe painful spasms in response to unexpected 
noise, startle or emotional upset. These spasms initially 
occurred about 1–2/month and lasted about 30–60 min 
but over time increased in both frequency and duration. 
These episodes were associated with drenching sweats 
and fear. She has had several falls and injuries due to sud-
den muscle spasms. She also reported generalised anxiety 
since the onset of the illness in 2002 and specific pho-
bias to open spaces, walking unaided and being among a 
crowd of people. She had felt depressed at times which 
she attributed to the disabling nature of the illness which 
had curtailed her independence. In 2007, she was diag-
nosed with diabetes mellitus, which required insulin to 
achieve normal glycaemic control. In 2014, she was found 
to be biochemically hypothyroid and commenced on thy-
roxine replacement. She has had 3 repeated magnetic 
resonance imaging (MRI) of the brain and spinal cord 
since 2002, all of which were reported as normal. After 
extensive investigation she had been given a presumptive 
diagnosis of ‘non-compressive myelopathy’ of unknown 
aetiology and treated with diazepam and baclofen. How-
ever, her condition continued to deteriorate with time.
On examination in 2015 she had hyperlordosis of 
the lumbar spine (Fig.  1) due to rigid contraction of 
her thoracolumbar paraspinal muscles associated with 
stony-hard, board-like rigidity of her anterior abdominal 
muscles, markedly increased tone in both lower limbs, 
and more on the left with the left ankle being in a plan-
tarflexed posture. Clonus was absent. Muscle power was 
5/5 on the right and 4+/5 on the left. Knee jerks were 
brisk, ankle jerks were normal and the plantar responses 
were flexor. The sensory examination was normal. Her 
distribution of stiffness index was 3/6 (number of stiff 
areas, range 0–6) and heightened sensitivity index was 
7/7 (number of stimuli that induce muscle spasms, range 
0–7) while the modified Rankin score (mRS, range 0–6) 
was 4. Examination of her upper limbs and cranial nerves 
were normal. General and other system examinations 
were normal. Her blood pressure was 130/80 mmHg.
Routine haematological and biochemical investigations 
including blood counts, inflammatory markers, liver 
function and renal function tests were normal. Blood 
glucose was maintained within normal limits with sub-
cutaneous insulin. Her thyroid stimulating hormone level 
had been over 100  miU/ml before commencement of 
thyroxine. Anti-thyroglobulin antibodies were 102.16 IU/
ml (normal 0.00–4.11). Anti-thyroid peroxidase antibod-
ies were 1076 IU/ml (normal 0.5–5.6). Antinuclear anti-
bodies and rheumatoid factor were normal. Anti-GAD 
antibodies were 15,500  IU/ml (normal <5). Electromyo-
graphy (EMG) of abdominal and paraspinal muscles 
showed continuous motor unit activity (CMUA) at rest. 
Nerve conduction studies were normal.
She was treated with intravenous immunoglobulin 
(IVIg) 0.4  g/kg/d for 5  days and commenced on lev-
etiracetam 250  mg BD later increased to 500  mg BD, 
mycophenolate mofetil 250  mg BD later increased to 
500  mg BD and increasing doses of diazepam, baclofen 
and tizanidine. Humulin insulin and thyroxine were 
titrated to achieve normoglycemia and normal TSH lev-
els. Medical treatment was combined with physiotherapy. 
Her distribution of stiffness index reduced to 1/6 after 
1  month and the heightened sensitivity index reduced 
to 1/7 after 3 months while the mRS improved to 3 after 
3  months and has remained that at 1  year follow up. 
Additionally, her susceptibility to excessive startle and 
anxiety resolved with treatment, but she continued to 
have agoraphobia and phobia to open spaces, albeit to a 
lesser degree. She had a second course of IVIg, 6 months 
after the initial treatment and has remained clinically sta-
ble on immunosuppressive and symptomatic medication.
Discussion
SPS is most common in the fourth and fifth decades of 
life affecting more women than men [5, 6]. Our patient 
fulfilled the clinical criteria of SPS which includes (1) 
muscular rigidity in limbs and axial muscles; (2) continu-
ous co-contraction of agonist and antagonist muscles; 
(3) episodic spasms precipitated by unexpected noises, 
Fig. 1 Hyperlordosis of lumbar spine associated with rigid anterior 
abdominal wall muscles demonstrated by prominently defined 
rectus abdominis
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tactile stimuli or emotional upset; (4) absence of any 
other neurological disease that could explain stiffness 
and rigidity; and (5) presence of anti-GAD antibodies 
(GAD-Abs) in serum [7]. She had increased paraspinal 
muscle tone causing hyperlordosis, which is a hallmark 
clinical sign of SPS (Fig. 1). The diagnosis in our patient 
was clinically supported by the characteristic, but not 
unique, EMG finding of CMUA and the detection of 
serum GAD-Abs in high titre. GAD-Abs are most com-
monly detected in type 1 diabetes mellitus (T1DM), 
which occurs in about 40 % of patients with SPS as seen 
in our patient, but the titre in T1DM is markedly lower 
than that of SPS [8]. Although high titres of GAD-Ab in 
the range seen in SPS (>1000 IU/ml) have been reported 
in some cases of cerebellar ataxia and epilepsy [8, 9], the 
prevalence of GAD-Abs in those diseases is rare. Other 
organ specific autoimmune diseases and autoantibodies, 
such as the thyroid disease in our patient, are found in 
around 40 % of patients with SPS [6].
A very typical but poorly appreciated feature is the 
marked anxiety, paroxysmal fear, excessive startle and 
specific phobias such as of open spaces that are fre-
quently found in these patients. The rate of specific pho-
bia in SPS is at least five times greater than in the general 
population [10]. These symptoms coupled with emo-
tionally triggered spasms often contribute to the initial 
misdiagnosis as neurosis and a delay in the diagnosis of 
SPS. There was a delay in diagnosis of 12  years in our 
patient, possibly due to the slow evolution of the disease 
coupled with a low index of suspicion. The average time 
from symptom onset to diagnosis has been reported to 
be 6.2 years (range 1–18 years) [6].
SPS remains a clinical diagnosis supported by typi-
cal EMG findings and positive serology for GADAbs. 
Other causes of rigidity and spasms need exclusion. 
These include chronic tetanus, neuromyotonia, dysto-
nia, hyperekplexia with late presentation, spinal multiple 
sclerosis or paraneoplastic myelitis, intrinsic spinal cord 
tumours or syrinx and psychologically determined disor-
ders. Our patient presented with typical features of SPS 
supported with EMG features and high-titre GAD-Abs. 
There was no clinical or neurophysiological evidence of 
hyperekplexia, dystonia, myotonia or upper motor neu-
ron syndromes. However, the severe rigidity of her limbs 
had been misdiagnosed as spasticity even though she had 
not had upper motor neuron signs such as extensor plan-
tar responses, clonus or a sensory level, thus contributing 
to a delay in diagnosis and appropriate treatment.
The clinical severity of SPS can be graded according 
to the distribution of stiffness index, which records the 
number of stiff areas ranging from 0 (none) to 6 and the 
heightened sensitivity index, which records the number 
of stimuli that induces spasms ranging from 0 (none) 
to 7 [6]. Our patient showed remarkable and sustained 
improvement of both these indices and mRS few months 
after initiating immunomodulatory and immunosup-
pressive therapies. IVIg is the only immunomodula-
tory treatment that has been shown to confer significant 
improvement in a randomised, double-blinded, placebo-
controlled crossover trial [11].
It has been suggested that GAD-Abs are pathogenic 
and cause loss of GABAergic inhibition in the CNS [12] 
that is responsible for the muscle spasms and rigidity. 
However, given that GAD is an intracellular protein that 
is not thought to be accessible to circulating antibodies, 
it may be that GAD-Abs are part of a wider autoimmune 
process rather than the specific cause of the disease [13, 
14].
Conclusions
Our case report highlights the need for a high index of 
clinical suspicion in order to diagnose a rare, but progres-
sively disabling autoimmune central nervous system dis-
order for which effective treatment is available. It further 
adds to map the worldwide distribution of SPS in differ-
ent populations.
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